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Deletion of genes encoding PU.1 and Spi-B in B cells impairs differentiation and
induces pre-B cell acute lymphoblastic leukemia
Kristen M. Sokalski,1 Stephen K. H. Li,1,2 Ian Welch,3 Heather-Anne T. Cadieux-Pitre,3 Marek R. Gruca,1,2 and
Rodney P. DeKoter1,2
1Department of Microbiology and Immunology and the Centre for Human Immunology, Schulich School of Medicine & Dentistry, The University of Western
Ontario, London, ON; 2Division of Genetics and Development, Children’s Health Research Institute, Lawson Research Institute, London, ON; and 3Department
of Animal Care and Veterinary Services, The University of Western Ontario, London, ON

esis, mice were generated lacking both
PU.1 and Spi-B in the B-cell lineage. Unlike mice lacking PU.1 or Spi-B, mice
deficient in both PU.1 and Spi-B in the
B-cell lineage had reduced frequencies of
B cells as well as impaired B-cell differentiation. Strikingly, all PU.1 and Spi-B–
deficient mice developed pre-B cell acute
lymphoblastic leukemia before 30 weeks

of age. Pre-B cells accumulated in the
thymus resulting in massive thymic enlargement and dyspnea. These findings
demonstrate that PU.1 and Spi-B are essential transcriptional regulators of B-cell
differentiation as well as novel tumor
suppressors in the B-cell lineage. (Blood.
2011;118(10):2801-2808)

Introduction
The E26 transformation-specific (Ets) transcription factor PU.1
(encoded by the gene Sfpi1 in mice and SPI1 in humans) is required
for generating lymphoid progenitor cells and is a key regulator of
B-cell fate specification.1,2 However, conditional deletion of the
Sfpi1 gene under control of the B cell–specific Cd19 locus results
in minimal perturbation of B-cell development and function.3,4
Spi-B (encoded by Spib) is expressed in developing B cells5 and
interacts with DNA binding sites identical to PU.1.6 Several studies
suggest that PU.1 and Spi-B functions are complementary. Spi-B
can partially replace PU.1 in myeloid and B-cell differentiation.7,8
In addition, Sfpi1⫹/⫺Spib⫺/⫺ mice have severely reduced frequencies of splenic follicular (FO) B cells compared with either
Sfpi1⫹/⫺ or Spib⫺/⫺ mice.9 We hypothesized that PU.1 is partially
redundant after B-cell commitment because of complementation by
Spi-B. To test this hypothesis, we generated mice that delete a
conditional Sfpi1lox allele under control of the B cell–specific Cd19
locus on a Spib⫺/⫺ background (CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice).
We report here that CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice have reduced
frequencies of B cells and impaired B-cell differentiation. Strikingly, all CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice develop pre-B cell
acute lymphoblastic leukemia (ALL) with thymic involvement
before 30 weeks of age. These findings demonstrate that PU.1 and
Spi-B have complementary function as essential transcriptional
regulators and novel tumor suppressors in the B-cell lineage.

Methods
Breeding and care of mice
CD19Cre/Cre mice10 were purchased from The Jackson Laboratory (stock no.
006785) and mated to Sfpi1lox/lox mice2 to generate CD19⫹/CreSfpi1⫹/lox mice.

These were mated to Spib⫺/⫺ mice11 to generate CD19⫹/CreSfpi1⫹/loxSpib⫹/⫺
mice that were intercrossed to generate CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice. Mice
used in this study were on the C57Bl/6 background and were generated by
mating CD19⫹/CreSfpi1lox/lox males to CD19⫹/⫹Sfpi1lox/lox females or by mating
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ males to CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺ females. Mouse
care was monitored under an approved animal use subcommittee protocol in
accord with the University of Western Ontario Council on Animal Care.
PCR and genotyping
Genotyping of mice was performed using standard PCR. Quantitative PCR
(qPCR) was performed using a Rotor-Gene 6000 instrument (Corbett Life
Sciences). The relative frequency of intact Sfpi1lox or deleted Sfpi1⌬ alleles was
normalized to the frequency of ␤-actin promoter genomic DNA, using the
comparative threshold cycle method.12 The relative frequencies of mRNA
transcripts were measured by reverse transcription (RT)-qPCR and were normalized to the frequency of glyceraldehyde-3-phosphate dehydrogenase (Gapdh)
transcripts. Primers are described in supplemental Table 1 (available on the Blood
Web site; see the Supplemental Materials link at the top of the online article).
Histologic and microscopic analysis
Mice were euthanized by lethal intraperitoneal injection of 540 mg/mL sodium
pentobarbital (Euthanyl Forte; Bimeda-MTC, Animal Health). Tissues were
fixed in 10% neutral buffered formalin. Femurs were decalcified for 96 hours in
26% formic acid (TBD-2; Thermo Fisher Scientific). Tissues were paraffin
embedded, sectioned, and stained with hematoxylin and eosin. High-resolution
micrographs were captured using a Q-Color3 digital camera (Olympus).
Flow cytometry
Analysis of antibody-stained cells was performed using an FACSCalibur
system (BD Biosciences). Sorting of antibody-stained cells was performed
using an FACSAria II system. The sorted cells were determined to be of at
least 98% purity on reanalysis using the FACSAria II system. Data analysis
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The E26 transformation-specific (Ets) transcription factor PU.1 is required to generate lymphoid progenitor cells from hematopoietic stem cells, but it is not required
to generate B cells from committed B-cell
lineage progenitors. We hypothesized that
PU.1 function in B-cell differentiation is
complemented by the related Ets transcription factor Spi-B. To test this hypoth-
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was performed using FlowJo 9.1 software (TreeStar). Antibodies were
purchased from eBioscience and included phycoerythrin (PE)–conjugated
anti-CD19 (1D3), allophycocyanin-conjugated anti-B220 (RA3-6B2), PECy5–conjugated anti-IgM (II/41), PE-conjugated anti-CD93 (AA4.1),
fluorescein isothiocyanate (FITC)–conjugated anti-CD23 (B3B4), FITCconjugated anti-CD21 (eBio8D9), FITC-conjugated anti–BP-1 (6C3), biotinconjugated anti-CD4 (H129.19), allophycocyanin-conjugated anti-CD8a (536.7), FITC anti-CD44 (1M7), and PE-Cy5–conjugated anti-CD45.2. (104).
Statistical analysis
All data are reported as mean ⫾ SD of the mean. Statistical significance was
determined using a Student t test unless otherwise indicated. P values ⬍ .05
were considered significant. For all figures, *P ⬍ .05, **P ⬍ .01, and
***P ⬍ .001. Statistical analysis was performed using Prism 5.0 (GraphPad Software).

Results
CD19ⴙ/CreSfpi1lox/loxSpibⴚ/ⴚ mice have reduced frequencies and
impaired differentiation of B cells

Mice were analyzed lacking PU.1 in the B-cell lineage
(CD19⫹/CreSfpi1lox/lox), Spi-B in the germ line (CD19⫹/⫹Sfpi1lox/lox
Spib⫺/⫺), or Spi-B in the germ line and PU.1 in the B-cell lineage
(CD19⫹/CreSfpi1lox/loxSpib⫺/⫺). As reported previously,3,4,11 6- to
10-week-old mice lacking either PU.1 or Spi-B had frequencies of
B cells similar to that of C57Bl/6 mice (Figure 1A-C). However,
mice lacking both PU.1 and Spi-B in the B-cell lineage had 3-fold
reduced frequencies of splenic B cells compared with that of

C57Bl/6 mice (Figure 1A-C). Our laboratory recently showed that
PU.1 and Spi-B are important for generating splenic FO B cells.9
Therefore, we determined frequencies of IgM⫹ CD23⫹ FO and
IgMhi CD21hi marginal zone (MZ) B cells in the spleen of
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ and control mice. The frequency of
splenic IgM⫹CD23⫹ FO B cells was reduced more than 3-fold in
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice compared with C57Bl/6 mice
(Figure 1D top panels, E). FO B-cell frequencies were slightly but
significantly reduced in mice lacking either PU.1 or Spi-B (Figure
1E). In contrast, the frequencies of splenic IgMhi CD21hi MZ B cells
were more than doubled in frequency in CD19⫹/CreSfpi1lox/loxSpib⫺/⫺
mice compared with C57Bl/6 mice as well as significantly increased in frequency in mice lacking either PU.1 or Spi-B (Figure
1D bottom panels, F). Therefore, fewer B cells and in particular
fewer FO B cells were generated in the absence of PU.1 and Spi-B.
It has been reported previously that Tcf3⫹/⫺ mice have reduced
frequencies of FO B cells and increased frequencies of MZ
B cells.13 Therefore, the proteins E12 and E47, encoded by Tcf3,
might play a role in reduction of FO B-cell frequencies by PU.1 and
Spi-B. To test this idea, FO B cells were sorted from the spleen of
wild-type, CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺, and CD19⫹/CreSfpi1lox/loxSpib⫺/⫺
mice. RT-qPCR analysis was performed to measure the relative
frequencies of mRNA transcripts encoding E12, E47, Id2, and
Id3.14,15 As a control, Fcer2a transcripts encoding CD23 were
examined because this gene is activated by PU.1 and Spi-B in FO
B cells.9 E12, E47, Id2, Id3, and Fcer2a transcripts were significantly reduced in sorted FO B cells lacking Spi-B, or both PU.1 and
Spi-B (supplemental Figure 1A). E12 and E47 transcripts also were
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Figure 1. Six- to 10-week-old CD19ⴙ/CreSfpi1lox/loxSpibⴚ/ⴚ mice have
reduced follicular B cell frequencies. (A) Reduced B-cell frequencies in
the spleen of CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice compared with C57Bl/6
mice. Flow cytometric analysis was performed to determine the frequency
of B cells expressing CD19 and B220 (top panels) or surface IgM and
B220 (bottom panels) in the spleen of mice of the indicated genotypes.
(B) Quantitation of the frequency of splenic B cells expressing CD19 and
B220 for groups of 5 mice of the indicated genotypes. (C) Quantitation of
the frequency of splenic B cells expressing surface IgM and B220 for
groups of 5 mice of the indicated genotypes. (D) Reduction of FO B-cell
frequency and increase of marginal zone (MZ) B-cell frequency in the
spleen of CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice. Flow cytometric analysis was
performed to determine the relative frequency of FO B cells (IgM⫹CD23⫹,
indicated by ovals in top panels) and MZ B cells (IgMhiCD21hi, indicated by
ovals in bottom panels) in the spleen of mice of the indicated genotypes.
Results are shown gated on mature B220⫹CD93⫺ B cells. (E) Quantitation
of the frequency of splenic FO B cells (B220⫹CD93⫺IgM⫹CD23⫹) for
groups of 5 mice of the indicated genotypes. (F) Quantitation of the
frequency of splenic MZ B cells (B220⫹CD93⫺IgMhiCD21hi) for groups of 5
mice of the indicated genotypes.
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reduced in sorted FO B cells from Sfpi1⫹/⫺Spib⫺/⫺ (PUB) mice9
(supplemental Figure 1B). Therefore, FO B-cell frequencies might
be reduced in CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice at least in part as a
consequence of reduced levels of E12 and E47.
Next, the frequencies of immature transitional B cells expressing B220 and CD93 (AA4.1), a marker of immaturity,16 were
examined in CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ and control mice. Splenic
CD93⫹ transitional B-cell frequencies were increased ⬃ 4-fold by
deficiency of PU.1 in B cells, ⬃ 2-fold by deficiency of Spi-B, and
⬃ 4-fold by deficiency of both PU.1 and Spi-B (Figure 2A-B).
Despite the overall increase in transitional B-cell frequencies, the
frequencies of IgM⫹CD23⫹ transitional-2 or IgMlowCD23⫹ transitional-3 cells were reduced ⬎ 5-fold in the absence of both PU.1
and Spi-B (Figure 2C-F). Therefore, splenic transitional B-cell differentiation, as measured by down-regulation of CD93 and up-regulation of
CD23, is impaired in the absence of PU.1 and Spi-B.
A qPCR assay was designed to determine frequencies of
intact (Sfpi1lox) or deleted (Sfpi1⌬) alleles in B cells from
CD19⫹/Cre Sfpi1lox/loxSpib⫺/⫺ and control mice (Figure 3A).
CD93⫺B220⫹ CD19⫹ B cells were sorted from the spleen of
wild-type, CD19⫹/⫹ Sfpi1lox/loxSpib⫺/⫺, or CD19⫹/CreSfpi1lox/loxSpib⫺/⫺
mice and used to prepare genomic DNA for qPCR analysis (Figure
3B). The frequency of intact Sfpi1lox alleles was ⬃ 20% in B cells
from 8-week-old CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice compared with

CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺ mice, indicating that the Sfpi1lox allele
deletion frequency was ⬃ 80% (Figure 3C). Thus, Sfpi1lox deletion
under the control of CD19Cre was not complete by 6-10 weeks of age.
Expansion of an abnormal pre-B cell population in 11- to
18-week-old CD19ⴙ/CreSfpi1lox/loxSpibⴚ/ⴚ mice

At 11 to 18 weeks of age, the frequency of B220⫹CD19⫹ B cells in
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice was reduced to 13% compared
with 18% of splenocytes at 6-10 weeks of age (Figure 4A; compare
with Figure 1B). The frequency of deleted (Sfpi1⌬) alleles in sorted
splenic B220⫹CD19⫹ B cells was increased 6.4-fold in a 17-weekold CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mouse compared with an 8-weekold mouse (Figure 4B), suggesting that the frequency of deletion of
Sfpi1lox alleles progressed with age under the control of CD19Cre, as
reported previously.3 Next, bone marrow B-cell development was
examined. In CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice, the frequency of
bone marrow BP-1⫹ pre-B cells17 was increased compared with
CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺ mice (Figure 4C). Interestingly, the
spleens of 7/9 11- to 18-week-old CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice
contained high frequencies of an abnormal B-cell population that
expressed CD19 but little or no B220 (Figure 4D). The lack of
B220 expression on abnormal B cells may be the consequence of
loss of PU.1-dependent Cd45 transcription.18 Further analysis of
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Figure 2. Impaired transitional B-cell differentiation in mice deficient in PU.1 and/or Spi-B. (A) Increased splenic transitional B-cell frequencies in mice deficient in PU.1
or Spi-B. Flow cytometric analysis was performed to determine the frequency of transitional B cells expressing both B220 (x-axis) and CD93 (y-axis) in the spleen of 6- to
10-week-old mice of the indicated genotypes (see 4 panels). (B) Quantitation of results shown in Panel A for groups of 5 mice of each indicated genotype. The frequency of
CD93⫹ cells is shown gated on B220⫹ cells. (C) Altered differentiation of splenic transitional B cells in mice deficient in PU.1 or Spi-B. Flow cytometric analysis was performed
to determine the frequency of transitional-1 (IgM⫹CD23⫺), transitional-2 (IgM⫹CD23⫹), and transitional-3 (IgMlowCD23⫹) B cells (indicated by boxes and legend in right panel).
Results shown were gated on B cells expressing both B220 and CD93. (D-F) Quantitation of results shown in panel C for transitional-1, transitional-2, or transitional-3 B cells
for groups of 5 mice of the indicated genotypes.
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these abnormal B cells showed that they did not express CD23,
CD21, or surface IgM but that they uniformly expressed high levels

Figure 4. Identification of an abnormal pre-B cell population
in 11- to 18-week-old CD19ⴙ/CreSfpi1lox/loxSpibⴚ/ⴚ mice.
(A) B-cell frequencies are severely reduced in 11- to 18-week-old
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice. Flow cytometric analysis was
performed to determine the frequency of splenic B cells expressing CD19 and B220 in the spleen of mice of 11- to 18-week-old
mice of the indicated genotypes. Seven mice per group were
analyzed. (B) Measurement of deleted (Sfpi1⌬) allele frequencies
in B cells from 6- to 10-week-old and 11- to 18-week-old
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice. Using qPCR, primers cko1 and
cko2 (supplemental Table 1) were used to determine relative
frequencies of Sfpi1⌬ alleles in B cells enriched from mice of the
indicated genotype and age. The Sfpi1⌬ allele frequency in an
8-week-old CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ B cells was set to
1.00 (left bar), and the Sfpi1⌬ allele frequency in a 17-week-old
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ B cells is expressed as fold increase
relative to this value (right bar). qPCR also was performed on
C57Bl/6 B cell genomic DNA (center bar) as an additional negative control to demonstrate specificity of the qPCR reaction.
(C) Abnormal pre-B cell frequency in bone marrow of a 13-weekold CD19⫹/Cre Sfpi1lox/lox Spib⫺/⫺ mouse. Flow cytometric analysis
was used to determine the bone marrow pre-B cell frequencies
expressing BP-1 on their cell surface from 13-week-old mice of
the indicated genotypes. The histograms shown are gated on
B220⫹CD43⫹ bone marrow cells. (D) Appearance of an abnormal
B cell population expressing low levels of B220. Flow cytometric
analysis was performed on splenocytes from 18-week-old mice of
the indicated genotypes using antibodies recognizing CD19 or
B220. CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice had a CD19⫹ B220low
population in addition to the CD19⫹B220⫹ B-cell population (right
panel, dashed box). (E-F) Identification of abnormal CD19⫹B220low
cells as pre-B cells. Flow cytometric analysis using antibodies
recognizing the indicated cell surface markers was used to
determine the identity of gated CD19⫹B220⫹ B cells in
CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺ mice (E) or of gated CD19⫹B220low
B cells in CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice (F). Gates are shown
as dashed boxes in panel A. Results shown are representative of
9 mice analyzed.

of CD93 and BP-1 (Figure 4E-F). A CD19⫹sIgM⫺CD93⫹BP-1⫹
phenotype is most consistent with that of pre-B cells.16,17 In
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Figure 3. Measurement of Sfpi1lox allele deletion
frequency. (A) Schematic of the Sfpi1lox allele encoding
PU.1. Arrowheads indicate loxP or lox66 sequences. The
thick line extending from the 5⬘ loxP sequence indicates
unique DNA sequence derived from the targeting vector.
Arrows indicate locations recognized by PCR primers.
Names of primers are indicated. DNA sequence of the
Sfpi1lox allele was determined by cloning and sequencing
using primers listed in supplemental Table 1. (B) Enrichment
of mature B cells by cell sorting. CD93⫺CD19⫹B220⫹ B cells
were enriched from the spleen of 8-week-old wild-type (WT),
CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺, or CD19⫹/CreSfpi1lox/loxSpib⫺/⫺
mice by flow cytometric cell sorting. Genomic DNA was
prepared from sorted cells and used as template for qPCR
analysis. (C) Measurement of Sfpi1lox allele frequencies
using qPCR. Primers lox-exon4 fwd and lox-exon4 rev
(supplemental Table 1) were used to determine relative
frequencies of intact Sfpi1lox alleles in B cells enriched
from mice of the indicated genotypes. The Sfpi1lox allele
frequency in CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺ B cells was set to
1.00 (left bar), and the relative Sfpi1lox allele frequency in
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ B cells was expressed as a decimal (right bar). qPCR also was performed on C57Bl/6 B cell
genomic DNA (center bar) as an additional negative control to
demonstrate specificity of the qPCR reaction.
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summary, bone marrow and peripheral B-cell differentiation in
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice were characterized by an increase in frequency of an abnormal pre-B cell population.
Pre-B ALL with thymic involvement in
CD19ⴙ/CreSfpi1lox/loxSpibⴚ/ⴚ mice

No indications of illness were observed in CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺
control littermate mice at any age. In contrast,
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice required euthanasia at a median
age of 20 weeks for female mice and 21.7 weeks for male mice
because of labored breathing (dyspnea; Figure 5A). The difference
between males and females was not statistically significant
(P ⫽ .0647, using the Mantel-Cox test). Postmortem analysis
indicated that dyspnea was caused by an enlarged thymus that filled
the chest cavity (Figure 5B). Spleen and liver were consistently
enlarged (Figure 5B), whereas lymph nodes were enlarged in one
third of mice. To determine the cell type responsible for infiltration

and dysfunction of tissues; thymus, spleen, bone marrow, lymph
nodes, and blood from moribund CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice
and age-matched CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺ littermates were examined. Histologic analysis of the thymus revealed that the normal
architecture of the organ was no longer recognizable and was
replaced with sheets of generally uniform tumor cells (Figure
5C-D). The cells were ⬃ 12-15 m and were loosely arranged. The
cells had none to scant lightly basophilic cytoplasm. Nuclei were
intermediate in size, with moderate heterochromatin and inconspicuous or occasionally 1 centrally located nucleolus. The rate of
mitosis was less than one per high-power field. There was little
variation in either cellular or nuclear size. In the thymus, there was
a high degree of apoptosis suggested by a “starry sky” appearance
caused by invading macrophages (Figure 5C). In the liver there
were large numbers of tumor cells expanding sinusoids diffusely
with some periportal accumulation (Figure 5E-F). Tumor cells also
extensively infiltrated the spleen (supplemental Figure 1A), lymph
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Figure 5. Pre-B ALL with thymic involvement in
CD19ⴙ/CreSfpi1lox/loxSpibⴚ/ⴚ mice. (A) Kaplan-Meier survival plot for aging mice of the indicated genotype and sex.
(B) Enlarged thymus (arrow), enlarged spleen, and enlarged
liver are shown in a moribund CD19⫹/CreSfpi1lox/loxSpib⫺/⫺
mouse. (C) Histology of the thymus in a moribund
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mouse (original magnification ⫻4). (D) Enlargement of thymic section shown in
panel C, original magnification ⫻60. (E) Histology of the
liver in moribund CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice. (F) Enlargement of liver section shown in panel E to demonstrate
the presence of lymphocytes in sinusoids, original magnification ⫻60. (G) High frequency of immature B cells in the
thymus of a moribund CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mouse.
Flow cytometric analysis was performed to determine
the frequency of cells expressing the indicated cell
surface markers in the thymus of a moribund
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mouse. (H) Measurement of
Sfpi1lox allele frequencies in thymic pre-B cells. qPCR
was performed to determine the relative frequency of
intact Sfpi1lox alleles in pre-B cells from the thymus of a
moribund CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mouse (right bar).
As a control, the Sfpi1lox allele frequency in splenic B cells
enriched from an 8-week-old CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺
mice was determined and set to 1.00 (left bar). qPCR also
was performed on C57Bl/6 B cell genomic DNA (center
bar) as an additional negative control to demonstrate
specificity of the qPCR reaction.

2806

SOKALSKI et al

BLOOD, 8 SEPTEMBER 2011 䡠 VOLUME 118, NUMBER 10

Figure 6. Reduced PU.1 levels induce reduced expression of transcripts encoding BLNK. (A) Changes in frequencies of mRNA transcripts
in CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ pre-B ALL cells. Cell sorting was used to
enrich B220low CD19⫹ pre-B ALL cells from the spleen of 17-week-old
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice, and as a control, B220⫹ CD19⫹ B cells
from the spleen of 17-week-old CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺ mice (see
Figure 4D for illustration). RNA was prepared from each sample, and
RT-qPCR was used to measure relative frequencies of steady-state
mRNA transcript levels for genes indicated in the x-axis. Transcript
frequencies were normalized to Gapdh transcript levels. The y-axis
represents fold change in transcripts in CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ preB ALL cells compared with CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ B cells. (B) Dosedependent reduction of Blnk transcript levels in response to reduced PU.1
levels. RNA was prepared from cultured pro-B cells generated from the
fetal wild-type (WT), Sfpi1BN/BN (BN), or Sfpi1Blac/Blac (Blac) mice. RT-qPCR
was performed as described above to determine relative frequencies of
Blnk transcripts.

Transcripts encoding BLNK/SLP-65 are reduced in
CD19ⴙ/CreSfpi1lox/loxSpibⴚ/ⴚ pre-B ALL cells

B-cell linker protein ([BLNK] also named SLP-65) is an intracellular adaptor protein that is expressed in B cells and is essential for
transduction of signals from the B-cell receptor.20 BLNK is
considered a tumor suppressor gene for pre-B ALL.21 Our laboratory previously noted that Blnk transcript levels were reduced in
cultured pro-B cell lines lacking PU.1 and Spi-B.22 To determine
whether Blnk transcript levels were reduced in pre-B ALL cells,
splenic B220lowCD19⫹ cells were enriched by cell sorting from
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice. As a control, B220⫹CD19⫹ B cells
were enriched from the spleen of CD19⫹/⫹Sfpi1lox/loxSpib⫺/⫺ littermates
(sorting scheme as shown in Figure 4D). RNA was prepared from
sorted cells and used as template for RT-qPCR analysis. As shown
in Figure 6A, genes encoding the ␣ subunit of the IL-7 receptor
(IL-7R␣, encoded by Il7r) and VpreB (Vpreb1), markers of

pre-B cell differentiation,23 were highly expressed in
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ leukemia cells compared with controls.
In contrast, Fcer2a transcripts (encoding CD23) were nearly undetectable, consistent with flow cytometry results in Figure 4F and a
requirement for PU.1 and/or Spi-B in Fcer2a transcription.9 Cd19
transcripts were reduced in CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ pre-B ALL
cells compared with controls, as expected, because these cells lack
one functional Cd19 allele. Finally, transcripts encoding the
transcription factor Pax-5 (Pax5), Bruton’s tyrosine kinase (Btk),
and BLNK (Blnk) were examined. Pax-5 and BLNK are known
tumor suppressor genes in human pre-B ALL,21,24 whereas Btk can
cooperate with BLNK as a tumor suppressor gene in mouse
models.25 Pax-5, Btk, and BLNK were reduced 2-fold, 4-fold, and
6-fold, respectively, in CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ pre-B ALL
cells compared with controls. To obtain additional evidence that
Blnk might be activated by PU.1, we determined relative Blnk
transcript levels in cultured pro-B cells that express distinct PU.1
concentrations as a consequence of engineered hypomorphic
mutant alleles.26 Compared with wild-type pro-B cells, Sfpi1BN/BN
pro-B cells express ⬃ 20% of normal PU.1 levels and expressed
significantly reduced Blnk transcript levels, whereas Sfpi1Blac/Blac
pro-B cells express ⬃ 2% of normal PU.1 levels and expressed
4-fold reduced Blnk transcript levels (Figure 6B). Thus, Blnk
transcript levels respond to PU.1 in a dose-dependent manner.
Together, these results suggest that Blnk transcription is activated
by PU.1.

Discussion
ALL is the most common form of cancer in young children, and
despite an 80% cure rate, represents a leading cause of leukemiarelated deaths in children and adults.27 Pre-B ALL is frequently
associated with mutations affecting genes that encode transcriptional regulators.28 Reduced PU.1 expression has been associated
with acute myelogenous leukemia in human patients,29,30 and is
sufficient to induce acute myelogenous leukemia in mouse models.31,32 There are several reports of reduced PU.1 levels in
lymphoid leukemia or lymphoma.33,34 Our studies establish that
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nodes (supplemental Figure 1B), and bone marrow (supplemental
Figure 1C). Lymphocyte counts were increased in the blood of
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice compared with CD19⫹/⫹Sfpi1lox/
loxSpib⫺/⫺ littermates (supplemental Figure 1D).
Flow cytometric analysis showed that 80% to 90% of
cells in the thymus, spleen, and lymph nodes of moribund
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice were CD19⫹ and expressed the
pre-B cell markers BP-1 and CD93 (Figure 5G; supplemental
Figure 2). The thymus contained only 5% to 8% T cells expressing
CD4 or CD8 and few double-positive cells (supplemental Figure
2A). Pre-B cells in the thymus expressed high levels of the
hyaluronic acid receptor CD44, a molecule with an established role
in tumor metastasis.19 Thymic pre-B cells expressed reduced levels
of total CD45 on their surface (supplemental Figure 2B), consistent
with the lack of B220 expression (Figure 5G) and a requirement for
PU.1 in activating Cd45 (encoding B220) in B cells.18 Finally, the
frequency of intact Sfpi1lox alleles was measured in pre-B cells
from the thymus of a 24-week-old CD19⫹/CreSfpi1lox/loxSpib⫺/⫺
mouse and determined to be ⬍ 1%, indicating near complete
deletion in tumor cells (Figure 5H). Together, these results suggest
that the disease in moribund CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice is
pre-B ALL.
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Sfpi1⫺/⫺Spib⫺/⫺ pro-B cells cultured on stromal layers with IL-7
proliferate more rapidly than wild-type pro-B cells, differentiate
into pre-B–like cells, and express reduced levels of Blnk transcripts.22 Therefore, pre-B ALL in CD19⫹/CreSfpi1lox/loxSpib⫺/⫺
mice might be caused in part by reduced Blnk expression in
response to reduced PU.1 and Spi-B.
There are several differences between pre-B ALL that develops
in Blnk⫺/⫺ or Blnk⫺/⫺Btk⫺/⫺ mice and what we report in
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice. First, disease occurs in 100% of
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice, whereas it occurs in ⬍ 80% of
Blnk⫺/⫺Btk⫺/⫺ mice by 5 months of age.25 Second, disease in
CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice is characterized by massive thymic enlargement, which was not reported in Blnk⫺/⫺Btk⫺/⫺ mice.
The molecular basis of migration of pre-B ALL cells into the
thymus in CD19⫹/CreSfpi1lox/loxSpib⫺/⫺ mice is not known. However, we note that cultured pro-B cells expressing reduced PU.1
levels ectopically express a number of T cell–specific genes.38
Therefore, it is possible that pre-B cells lacking PU.1 and Spi-B
express genes that promote homing to the thymus. More work will
be necessary to identify the exact genes and proteins involved.
In summary, our work establishes PU.1 and Spi-B as complementary tumor suppressors in developing B cells. The mouse
model that we describe should be useful for identifying pathways
of leukemogenesis that can be targeted at the molecular level by
novel therapies.
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